SCHEMBL3485808

SCHEMBL3485808

CCN(CC)C(C)ON1C(=O)c2ccccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 5/20 0.40
MAPT P10636 2/20 0.40
VDR P11473 2/20 0.40
KDM4E B2RXH2 1/20 0.40
F2 P00734 1/20 0.40
DRD3 P35462 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CASP3 P42574 1/20 0.38
HTT P42858 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3485769 0.98 GAA (0.41) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL15581867 0.77 GAA (0.46) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL4874091 0.77 GAA (0.46) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL2078111 0.76 KMT2A (0.49) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL4869158 0.75 GAA (0.47) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL3713532 0.75 GAA (0.47) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL929727 0.74 TDP1 (0.50) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL22721297 0.73 GAA (0.42) GAAKMT2AMEN1ALDH1A1MAPT
SCHEMBL31588065 0.73 CASP3 (0.48) GAAKMT2AMEN1RAB9AALDH1A1
SCHEMBL19351874 0.73 GAA (0.44) GAAKMT2AMEN1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140274903-A1 USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST NOVO NORDISK HEALTHCARE AG (CH) 2014-09-18 US disclosed
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest NOVO NORDISK HEALTHCARE A/G (CH) 2010-02-04 US disclosed
US-20060198819-A1 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest NOVO NORDISK HEALTHCARE A/G (CH) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060198819-A1 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest GALE, GALNT2, GALNT1 GAA 71/4885KMT2A 4257/4885MEN1 4412/4885
US-20140274903-A1 USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST GALE, GALNT2, GALNT1 GAA 71/4885KMT2A 4257/4885MEN1 4412/4885
US-20100028939-A1 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest GALE, GALNT2, GALNT1 GAA 71/4885KMT2A 4257/4885MEN1 4412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.